NCT01138384 2023-08-04
Study of Foretinib in Combination With Lapatinib in Patients With Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 1/2 Completed
Clinical Trials
8 trialsNCT01147484 2023-08-04
IND197
Canadian Cancer Trials Group
Phase 2 Completed
NCT00725764 2017-10-16
Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck
GlaxoSmithKline
Phase 2 Completed
NCT00725712 2017-08-24
Study of GSK1363089 in Metastatic Gastric Cancer
GlaxoSmithKline
Phase 2 Completed
NCT00742131 2017-07-31
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally to Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00743067 2017-07-26
A Dose Escalation Study of the Safety and Pharmacokinetics of GSK1363089 (Formerly XL880) Administered Orally Daily to Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT00920192 2017-07-18
Safety Study of Foretinib (GSK1363089) in Adults With Liver Cancer
GlaxoSmithKline
Phase 1 Completed
NCT00742261 2017-07-07
A Bioavailability Study of GSK1363089 in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed